All In Biotech

Drug Trial Radar · NCT01807221

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone

Last checked: Nov 20, 2026Latest source record: Jul 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,066 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,066

Actual

Start

Jun 17, 2013

Primary completion

Nov 11, 2014

Study completion Dec 9, 2014

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Mar 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess a new drug, BAY94-8862, given orally at different doses, to evaluate whether it was safe and can help the well-being of patients with worsening chronic heart failure and either type II diabetes with or without chronic kidney disease or kidney disease alone. These treatment doses were compared to eplerenone, another marketed drug approved to treat heart failure.

Conditions

  • Heart Failure

Interventions

  • Finerenone (BAY94-8862)Drug

  • PlaceboDrug

  • Inspra (eplerenone)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90Time frame: Baseline and Day 90

Locations

172 sites in 25 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Macon, Georgia

  • Site not named

    Baltimore, Maryland

  • Site not named

    Detroit, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Newark, New Jersey

  • Site not named

    Fairfield, Ohio

  • Site not named

    Concord, Australia

  • Site not named

    Prahran, Australia

  • Site not named

    Darlinghurst, New South Wales, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Salzburg, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Krems, Lower Austria, Austria

  • Site not named

    Graz, Styria, Austria

  • Site not named

    Graz, Styria, Austria

  • Site not named

    Innsbruck, Tyrol, Austria

  • Site not named

    Linz, Upper Austria, Austria

  • Site not named

    Burgas, Bulgaria

  • Site not named

    Pazardzhik, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Varna, Bulgaria

  • Site not named

    Québec, Canada

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Saint-Jean-sur-Richelieu, Quebec, Canada

  • Site not named

    Sherbrooke, Quebec, Canada

  • Site not named

    Jindřichův Hradec, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Prague, Czechia

Showing 40 of 172 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.